Vildan Ozkocaman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vildan Ozkocaman has a total of 286 co-authors. Here are the top co-authors by number of shared publications:
- Fahir Özkalemkaş
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey
73 shared publications - Tuba Ersal
Department of Hematology, Bursa Uludağ University Hospital, Bursa Uludağ University, 16059 Bursa, Türkiye
47 shared publications - İbrahim Ethem Pinar
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, 16059 Bursa, Turkey
33 shared publications - Fazıl Çağrı Hunutlu
Division of Hematology, Department of Internal Medicine, Bursa Sehir Training and Research Hospital, University of Health Sciences, Bursa 16009, Türkiye
28 shared publications - Bedrettin Orhan
Department of Hematology, Bursa Yuksek Ihtisas Training and Research Hospital, University of Health Science, Bursa 16310, Turkey
25 shared publications - Tuba Güllü Koca
Department of Hematology, Bursa Şehir Training & Research Hospital, University of Health Sciences, 16250 Bursa, Türkiye
24 shared publications
Latest Publications
- 11 November 2026
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
Posaconazole in Clinical Practice: A Narrative Review of Current Evidence and Expert Recommendations
Posaconazole is a broad-spectrum antifungal agent used to manage invasive fungal infections (IFIs), particularly in high-risk immunocompromised patients. It is active against a range of fungal pathogens, including Candida spp., Aspergillus spp., and Mucorales. The introduction of delayed-release tablets and intravenous formulations has significantly expanded its clinical utility by overcoming the pharmacokinetic limitations of the original oral suspension. Randomized controlled trials provide strong evidence supporting posaconazole as the preferred agent for primary antifungal prophylaxis in patients with acute myeloid leukemia, myelodysplastic syndromes, and allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. It has demonstrated superior efficacy over fluconazole and itraconazole in reducing the incidence of IFIs and associated mortality, earning strong recommendations in major international guidelines, including those of the European Conference on Infections in Leukemia (ECIL) and the Infectious Diseases Society of America (IDSA). Beyond prophylaxis, posaconazole’s role in treatment continues to expand. A pivotal randomized controlled trial has demonstrated its non-inferiority to voriconazole as first-line therapy for invasive aspergillosis, positioning it as an important first-line treatment option. Posaconazole also remains a key agent for salvage therapy or as an alternative for patients intolerant or refractory to other first-line agents such as liposomal amphotericin B. Its well-documented tolerability profile and availability in flexible dosing formulations support its use in prolonged treatment courses and complex clinical scenarios. The clinical landscape continues to evolve with the emergence of new at-risk populations, including patients receiving novel cancer immunotherapies and those affected by viral-associated fungal infections such as coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis. Despite these advances, significant practical challenges persist, including formulation-dependent pharmacokinetics, clinically relevant drug-drug interactions, and ongoing uncertainty regarding the role of therapeutic drug monitoring. This narrative review summarizes current evidence and offers expert experience for clinicians navigating the complexities of posaconazole use in both prophylaxis and treatment in daily clinical practice.
- 11 November 2026
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
Posaconazole in Clinical Practice: A Narrative Review of Current Evidence and Expert Recommendations
Posaconazole is a broad-spectrum antifungal agent used to manage invasive fungal infections (IFIs), particularly in high-risk immunocompromised patients. It is active against a range of fungal pathogens, including Candida spp., Aspergillus spp., and Mucorales. The introduction of delayed-release tablets and intravenous formulations has significantly expanded its clinical utility by overcoming the pharmacokinetic limitations of the original oral suspension. Randomized controlled trials provide strong evidence supporting posaconazole as the preferred agent for primary antifungal prophylaxis in patients with acute myeloid leukemia, myelodysplastic syndromes, and allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. It has demonstrated superior efficacy over fluconazole and itraconazole in reducing the incidence of IFIs and associated mortality, earning strong recommendations in major international guidelines, including those of the European Conference on Infections in Leukemia (ECIL) and the Infectious Diseases Society of America (IDSA). Beyond prophylaxis, posaconazole’s role in treatment continues to expand. A pivotal randomized controlled trial has demonstrated its non-inferiority to voriconazole as first-line therapy for invasive aspergillosis, positioning it as an important first-line treatment option. Posaconazole also remains a key agent for salvage therapy or as an alternative for patients intolerant or refractory to other first-line agents such as liposomal amphotericin B. Its well-documented tolerability profile and availability in flexible dosing formulations support its use in prolonged treatment courses and complex clinical scenarios. The clinical landscape continues to evolve with the emergence of new at-risk populations, including patients receiving novel cancer immunotherapies and those affected by viral-associated fungal infections such as coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis. Despite these advances, significant practical challenges persist, including formulation-dependent pharmacokinetics, clinically relevant drug-drug interactions, and ongoing uncertainty regarding the role of therapeutic drug monitoring. This narrative review summarizes current evidence and offers expert experience for clinicians navigating the complexities of posaconazole use in both prophylaxis and treatment in daily clinical practice.
- Open Access
Immunoglobulin A Subtype and Survival After Upfront Autologous Stem Cell Transplantation in Multiple Myeloma: A Real-World Cohort from the Bortezomib Era
Background: Immunoglobulin isotype is recorded at diagnosis in every patient with intact-immunoglobulin multiple myeloma, but is not retained in the ISS, R-ISS, or R2-ISS. Methods: We analyzed 196 consecutive patients with IgA or IgG myeloma who underwent upfront autologous stem cell transplantation at a single center (2009–2023). The primary endpoint was progression-free survival (PFS); overall survival (OS) was the secondary endpoint. Cox models used information available at transplantation, including the induction regimen and transplant year, in the complete-case set (n = 131) and after multiple imputation (n = 196). Results: Median PFS was 14.8 versus 30.5 months and OS 43.2 versus 94.2 months in IgA versus IgG patients (both p < 0.001). IgA isotype was associated with inferior PFS (adjusted HR 1.85, 95% CI 1.13–3.02; imputed HR 1.83, 95% CI 1.22–2.73). For OS, the HR was 1.68 (0.98–2.88) in the complete-case analysis and 1.91 (1.24–2.94) after imputation, so its magnitude is uncertain. Models with maintenance gave 1.87 and 1.82. Progression documentation differed by maintenance status. Cytogenetic data were too incomplete to assess independence from genomic risk. Conclusions: In a bortezomib-era transplant cohort, IgA isotype was associated with inferior PFS; the association with OS was of uncertain magnitude. The finding is hypothesis-generating and requires validation in cohorts with complete cytogenetic characterization.
Open AccessImmunoglobulin A Subtype and Survival After Upfront Autologous Stem Cell Transplantation in Multiple Myeloma: A Real-World Cohort from the Bortezomib Era
Background: Immunoglobulin isotype is recorded at diagnosis in every patient with intact-immunoglobulin multiple myeloma, but is not retained in the ISS, R-ISS, or R2-ISS. Methods: We analyzed 196 consecutive patients with IgA or IgG myeloma who underwent upfront autologous stem cell transplantation at a single center (2009–2023). The primary endpoint was progression-free survival (PFS); overall survival (OS) was the secondary endpoint. Cox models used information available at transplantation, including the induction regimen and transplant year, in the complete-case set (n = 131) and after multiple imputation (n = 196). Results: Median PFS was 14.8 versus 30.5 months and OS 43.2 versus 94.2 months in IgA versus IgG patients (both p < 0.001). IgA isotype was associated with inferior PFS (adjusted HR 1.85, 95% CI 1.13–3.02; imputed HR 1.83, 95% CI 1.22–2.73). For OS, the HR was 1.68 (0.98–2.88) in the complete-case analysis and 1.91 (1.24–2.94) after imputation, so its magnitude is uncertain. Models with maintenance gave 1.87 and 1.82. Progression documentation differed by maintenance status. Cytogenetic data were too incomplete to assess independence from genomic risk. Conclusions: In a bortezomib-era transplant cohort, IgA isotype was associated with inferior PFS; the association with OS was of uncertain magnitude. The finding is hypothesis-generating and requires validation in cohorts with complete cytogenetic characterization.
- Open Access
- 29 September 2026
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 52
A Rare Case of Lymphoma with Invasive Pulmonary Aspergillosis Developing Azole Resistance
This study reports a rare case of azole-resistant invasive pulmonary aspergillosis (IPA) in a patient with diffuse large B-cell lymphoma and to underscore the clinical relevance of emerging azole resistance in hematologic malignancies. Clinical, microbiological, and radiological findings were reviewed in a patient who developed IPA. Antifungal susceptibility testing was performed, and the clinical response was evaluated after modification of antifungal therapy. Despite antifungal treatment with voriconazole, azole resistance was detected. Switching back to amphotericin B resulted in marked clinical and radiological improvement, supporting the diagnosis of azole-resistant IPA. Azole resistance, though uncommon, is an increasingly important therapeutic concern in immunocompromised hosts. Early recognition and timely initiation of alternative agents such as amphotericin B may improve outcomes.
- 29 September 2026
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 52
Open AccessA Rare Case of Lymphoma with Invasive Pulmonary Aspergillosis Developing Azole Resistance
This study reports a rare case of azole-resistant invasive pulmonary aspergillosis (IPA) in a patient with diffuse large B-cell lymphoma and to underscore the clinical relevance of emerging azole resistance in hematologic malignancies. Clinical, microbiological, and radiological findings were reviewed in a patient who developed IPA. Antifungal susceptibility testing was performed, and the clinical response was evaluated after modification of antifungal therapy. Despite antifungal treatment with voriconazole, azole resistance was detected. Switching back to amphotericin B resulted in marked clinical and radiological improvement, supporting the diagnosis of azole-resistant IPA. Azole resistance, though uncommon, is an increasingly important therapeutic concern in immunocompromised hosts. Early recognition and timely initiation of alternative agents such as amphotericin B may improve outcomes.
- Open Access
- 18 September 2026
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 52
Exploratory Analysis of the C-Reactive Protein–Albumin–Lymphocyte Index and Progression-Free Survival in Early-Stage Classical Hodgkin Lymphoma
An easily accessible biomarker to predict early relapse in early-stage classical Hodgkin lymphoma (cHL) remains an unmet clinical need, and this study explored whether the C-reactive protein–albumin–lymphocyte (CALLY) index provides prognostic information in this setting. Ninety-three patients with early-stage cHL treated with doxorubicin, bleomycin, vinblastine, and dacarbazine between January 2010 and November 2024 were analyzed retrospectively. The CALLY index was calculated as (albumin × lymphocyte count) / C-reactive protein, and its prognostic performance was assessed using receiver operating characteristic analysis, Kaplan–Meier analysis, and Cox regression. Incremental value was assessed using Harrell's concordance index, time-dependent area under the curve, and integrated discrimination improvement, and these indices were compared with the neutrophil-to-lymphocyte, platelet-to-lymphocyte, and lymphocyte-to-monocyte ratios, the Prognostic Nutritional Index, and the International Prognostic Score. Median follow-up was 71 months, and 19 progression-free survival events occurred. The optimal cut-off was 5.87. Five-year progression-free survival was 58.7% versus 94.2% for low versus high values (p<0.001) and 52.6% versus 82.4% within the unfavorable subgroup (p=0.023). A low index was independently associated with worse progression-free survival (hazard ratio 3.44, 95% confidence interval 1.09–10.89, p=0.036) and adding it to the favorable/unfavorable classification improved discrimination (concordance index 0.745 to 0.807; time-dependent area under the curve at 60 months 0.767 to 0.846, p=0.030). The CALLY index showed the highest concordance index among the markers examined, although it significantly exceeded only the International Prognostic Score. Overall survival did not differ. A low pre-treatment CALLY index was therefore associated with shorter progression-free survival in early-stage cHL; this hypothesis-generating finding requires external and positron-emission-tomography-adapted validation.
- 18 September 2026
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 52
Open AccessExploratory Analysis of the C-Reactive Protein–Albumin–Lymphocyte Index and Progression-Free Survival in Early-Stage Classical Hodgkin Lymphoma
An easily accessible biomarker to predict early relapse in early-stage classical Hodgkin lymphoma (cHL) remains an unmet clinical need, and this study explored whether the C-reactive protein–albumin–lymphocyte (CALLY) index provides prognostic information in this setting. Ninety-three patients with early-stage cHL treated with doxorubicin, bleomycin, vinblastine, and dacarbazine between January 2010 and November 2024 were analyzed retrospectively. The CALLY index was calculated as (albumin × lymphocyte count) / C-reactive protein, and its prognostic performance was assessed using receiver operating characteristic analysis, Kaplan–Meier analysis, and Cox regression. Incremental value was assessed using Harrell's concordance index, time-dependent area under the curve, and integrated discrimination improvement, and these indices were compared with the neutrophil-to-lymphocyte, platelet-to-lymphocyte, and lymphocyte-to-monocyte ratios, the Prognostic Nutritional Index, and the International Prognostic Score. Median follow-up was 71 months, and 19 progression-free survival events occurred. The optimal cut-off was 5.87. Five-year progression-free survival was 58.7% versus 94.2% for low versus high values (p<0.001) and 52.6% versus 82.4% within the unfavorable subgroup (p=0.023). A low index was independently associated with worse progression-free survival (hazard ratio 3.44, 95% confidence interval 1.09–10.89, p=0.036) and adding it to the favorable/unfavorable classification improved discrimination (concordance index 0.745 to 0.807; time-dependent area under the curve at 60 months 0.767 to 0.846, p=0.030). The CALLY index showed the highest concordance index among the markers examined, although it significantly exceeded only the International Prognostic Score. Overall survival did not differ. A low pre-treatment CALLY index was therefore associated with shorter progression-free survival in early-stage cHL; this hypothesis-generating finding requires external and positron-emission-tomography-adapted validation.
- Open Access
- 24 August 2026
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 52
Assessment of Treatment Response in Patients Diagnosed with Waldenström’s Macroglobulinemia: Single-Center Experience
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by the production of monoclonal IgM. It may lead to symptoms such as hyperviscosity syndrome, anemia, and neuropathy. The indication for treatment is not based on a specific IgM level but is determined according to the clinical condition. This study aimed to retrospectively evaluate the treatment responses of patients diagnosed with WM between 2019 and 2024 at the Hematology Outpatient Clinic, Department of Internal Medicine, X Hospital. A total of 29 patients were included. Demographic characteristics and first- and second-line treatment responses were analyzed. The median age at diagnosis was 78 years; 69% were male. The median follow-up duration was 58.76 months. According to the IPS risk score, 20.7% were low risk, 27.6% intermediate risk, and 51.7% high risk. Treatment was initiated in 82% of patients, with rituximab plus bendamustine (R-Benda) being the most frequently used regimen. The overall response rate to first-line therapy was 75.9%. Among laboratory parameters, hemoglobin, platelet count, and LDH were identified as predictive factors for mortality. No significant difference in survival was observed according to IPS risk score at diagnosis (p>0.05). Survival differences were assessed using Kaplan-Meier analysis. Patients who achieved a response to first-line therapy demonstrated longer survival. Conventional immunochemotherapy remains an effective and tolerable treatment option in WM. However, larger comparative studies with novel agents such as Bruton tyrosine kinase (BTK) inhibitors are needed. Treatment decisions in WM should be individualized based on patient characteristics and clinical findings.
- 24 August 2026
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 52
Open AccessAssessment of Treatment Response in Patients Diagnosed with Waldenström’s Macroglobulinemia: Single-Center Experience
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by the production of monoclonal IgM. It may lead to symptoms such as hyperviscosity syndrome, anemia, and neuropathy. The indication for treatment is not based on a specific IgM level but is determined according to the clinical condition. This study aimed to retrospectively evaluate the treatment responses of patients diagnosed with WM between 2019 and 2024 at the Hematology Outpatient Clinic, Department of Internal Medicine, X Hospital. A total of 29 patients were included. Demographic characteristics and first- and second-line treatment responses were analyzed. The median age at diagnosis was 78 years; 69% were male. The median follow-up duration was 58.76 months. According to the IPS risk score, 20.7% were low risk, 27.6% intermediate risk, and 51.7% high risk. Treatment was initiated in 82% of patients, with rituximab plus bendamustine (R-Benda) being the most frequently used regimen. The overall response rate to first-line therapy was 75.9%. Among laboratory parameters, hemoglobin, platelet count, and LDH were identified as predictive factors for mortality. No significant difference in survival was observed according to IPS risk score at diagnosis (p>0.05). Survival differences were assessed using Kaplan-Meier analysis. Patients who achieved a response to first-line therapy demonstrated longer survival. Conventional immunochemotherapy remains an effective and tolerable treatment option in WM. However, larger comparative studies with novel agents such as Bruton tyrosine kinase (BTK) inhibitors are needed. Treatment decisions in WM should be individualized based on patient characteristics and clinical findings.
- Open Access
- 19 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (16) , 2643
Beyond the Thrombophilia Panel: Real-World Overuse, Limited Interpretability, and Poor Guideline Concordance in a Hematology Referral Cohort
Background: Hereditary thrombophilia testing is frequently performed outside guideline-supported indications, generating low-value results and diagnostic uncertainty. We evaluated the spectrum, laboratory validity, and appropriateness of thrombophilia testing in patients referred to hematology. Methods: This single-center retrospective cohort included 131 adults referred between September 2021 and November 2022 with a completed six-variant hereditary thrombophilia panel. Demographic, clinical, thrombotic, and laboratory data were reviewed, and testing appropriateness was assessed against the 2011 Turkish Society of Hematology guideline. Results: Ischemic stroke (25.2%), pulmonary embolism (21.4%), and recurrent pregnancy loss (16.0%) were the leading indications. Of 120 evaluable requests, only seven (5.8%) met guideline-supported criteria, and 42 (32.0%) were ordered during acute thrombosis. Factor V Leiden was associated with pulmonary embolism (48.6% vs. 22.1%, p = 0.003) and deep vein thrombosis (28.6% vs. 9.5%, p = 0.003), whereas ischemic stroke was less frequent among carriers (11.4% vs. 33.7%, p = 0.017). PAI-1, MTHFR c.1298A>C, and prothrombin G20210A showed no consistent associations. Of six low protein C results, only two were confirmed; none of eight low protein S results remained valid after timing and confirmation criteria were applied. Lupus anticoagulant was positive in 18 patients, yet only six underwent appropriately timed repeat testing, establishing four new antiphospholipid syndrome diagnoses. Conclusions: Most thrombophilia panels were ordered inappropriately, and test timing frequently compromised interpretability. Clinically meaningful information arose mainly from factor V Leiden and properly confirmed acquired thrombophilia testing. Targeted, indication-driven testing with strict attention to timing and confirmation should replace indiscriminate panel use.
- 19 August 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (16) , 2643
Open AccessBeyond the Thrombophilia Panel: Real-World Overuse, Limited Interpretability, and Poor Guideline Concordance in a Hematology Referral Cohort
Background: Hereditary thrombophilia testing is frequently performed outside guideline-supported indications, generating low-value results and diagnostic uncertainty. We evaluated the spectrum, laboratory validity, and appropriateness of thrombophilia testing in patients referred to hematology. Methods: This single-center retrospective cohort included 131 adults referred between September 2021 and November 2022 with a completed six-variant hereditary thrombophilia panel. Demographic, clinical, thrombotic, and laboratory data were reviewed, and testing appropriateness was assessed against the 2011 Turkish Society of Hematology guideline. Results: Ischemic stroke (25.2%), pulmonary embolism (21.4%), and recurrent pregnancy loss (16.0%) were the leading indications. Of 120 evaluable requests, only seven (5.8%) met guideline-supported criteria, and 42 (32.0%) were ordered during acute thrombosis. Factor V Leiden was associated with pulmonary embolism (48.6% vs. 22.1%, p = 0.003) and deep vein thrombosis (28.6% vs. 9.5%, p = 0.003), whereas ischemic stroke was less frequent among carriers (11.4% vs. 33.7%, p = 0.017). PAI-1, MTHFR c.1298A>C, and prothrombin G20210A showed no consistent associations. Of six low protein C results, only two were confirmed; none of eight low protein S results remained valid after timing and confirmation criteria were applied. Lupus anticoagulant was positive in 18 patients, yet only six underwent appropriately timed repeat testing, establishing four new antiphospholipid syndrome diagnoses. Conclusions: Most thrombophilia panels were ordered inappropriately, and test timing frequently compromised interpretability. Clinically meaningful information arose mainly from factor V Leiden and properly confirmed acquired thrombophilia testing. Targeted, indication-driven testing with strict attention to timing and confirmation should replace indiscriminate panel use.
- Open Access
- 17 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6350
Real-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology
Background: T-cell lymphomas (TCLs) constitute a heterogeneous group of mature T-cell neoplasms characterized by aggressive clinical behavior and poor outcomes, particularly in the relapsed/refractory (R/R) setting. Belinostat is a pan-HDAC inhibitor approved for R/R peripheral T-cell lymphomas. In this retrospective study, we analyze the real-world outcomes of single-agent belinostat in Turkish patients with R/R TCLs. Methods: Patients with R/R TCLs across Turkey who received at least one course of belinostat were included in the study. The primary end point was the overall response rate (ORR). The secondary end points included progression-free survival (PFS), overall survival (OS) and duration of response (DOR). Results: A total of 59 patients with R/R TCL were enrolled in the study, with a median age of 62 years. The median number of previous lines of therapy before belinostat was 2.5. The ORR for belinostat was 30.5% in the overall study cohort. Response assessment was available in 53 patients, among whom the ORR was 34% (18/53). The median PFS was 3 months. The median OS was 12 months, and the median DOR was not reached in responders. At least one adverse event occurred in 39.0% of patients. Conclusions: Belinostat produced objective responses in a subset of patients. These findings support belinostat as a potential individualized treatment option rather than a broadly effective standard for all patients with R/R TCLs. This multicenter real-world study demonstrates that the observed response rates closely mirror those reported in prospective clinical trials, confirming the reproducibility of belinostat efficacy in routine clinical practice.
- 17 August 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (16) , 6350
Open AccessReal-World Outcomes of Belinostat in Relapsed Refractory T-Cell Lymphomas: A Report from the Lymphoma Study Group of Turkish Society of Hematology
Background: T-cell lymphomas (TCLs) constitute a heterogeneous group of mature T-cell neoplasms characterized by aggressive clinical behavior and poor outcomes, particularly in the relapsed/refractory (R/R) setting. Belinostat is a pan-HDAC inhibitor approved for R/R peripheral T-cell lymphomas. In this retrospective study, we analyze the real-world outcomes of single-agent belinostat in Turkish patients with R/R TCLs. Methods: Patients with R/R TCLs across Turkey who received at least one course of belinostat were included in the study. The primary end point was the overall response rate (ORR). The secondary end points included progression-free survival (PFS), overall survival (OS) and duration of response (DOR). Results: A total of 59 patients with R/R TCL were enrolled in the study, with a median age of 62 years. The median number of previous lines of therapy before belinostat was 2.5. The ORR for belinostat was 30.5% in the overall study cohort. Response assessment was available in 53 patients, among whom the ORR was 34% (18/53). The median PFS was 3 months. The median OS was 12 months, and the median DOR was not reached in responders. At least one adverse event occurred in 39.0% of patients. Conclusions: Belinostat produced objective responses in a subset of patients. These findings support belinostat as a potential individualized treatment option rather than a broadly effective standard for all patients with R/R TCLs. This multicenter real-world study demonstrates that the observed response rates closely mirror those reported in prospective clinical trials, confirming the reproducibility of belinostat efficacy in routine clinical practice.
- Open Access
Pre-Transplant Endothelial Activation and Stress Index (EASIX) and Albumin-Modified mEASIX (mEASIX_alb) Predict Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Background and Objectives: Endothelial dysfunction is increasingly recognized as a key determinant of transplant outcomes. The Endothelial Activation and Stress Index (EASIX), originally validated in allogeneic stem cell transplantation, integrates markers of endothelial stress into a single composite score. Its prognostic role in autologous stem cell transplantation (ASCT) for multiple myeloma (MM) remains undefined. We evaluated the pre-transplant prognostic value of EASIX, an albumin-modified formulation (mEASIX_alb), and nutritional indices (Prognostic Nutritional Index [PNI] and Controlling Nutritional Status [CONUT] score) in a large MM-ASCT cohort. Materials and Methods: We retrospectively analyzed 274 MM patients who underwent ASCT at a single institution. The pre-ASCT EASIX (LDH × Creatinine/Platelets), mEASIX_alb (LDH × Creatinine/[Platelets × Albumin]), PNI (10 × Albumin [g/dL] + 0.005 × Lymphocyte count), and CONUT score were calculated from laboratory values obtained on day 3. Optimal binary cutoffs were determined by maximally selected rank statistics. Overall survival (OS) and progression-free survival (PFS) were analyzed with Cox models in which EASIX and mEASIX_alb were entered as continuous, log-transformed variables; binary cutoffs were used only for descriptive Kaplan–Meier illustration. Internal model validity was assessed by bootstrap resampling (B = 1000). Results: Over a median follow-up of 81.3 months, 150 patients (54.7%) died, and 207 (75.5%) experienced disease progression or death. Using illustrative cutoffs (EASIX > 0.471, mEASIX_alb > 0.208, PNI < 52.29), higher EASIX was associated with shorter OS (66.7 vs. 108.1 months; p = 0.012) and PFS (27.4 vs. 42.7 months; p = 0.018). In multivariable analysis, log-transformed EASIX (HR 1.40, 95% CI 1.10–1.77; p = 0.006) and mEASIX_alb (HR 1.38, 95% CI 1.09–1.73; p = 0.007) independently predicted OS after adjustment for baseline covariates (ISS stage, pre-transplant response, and age). EASIX remained independently prognostic in a day-100 landmark analysis (HR 1.35; p = 0.023). Critically, the PNI, prognostic for OS in univariate analysis (HR 0.973; p = 0.038), did not provide independent incremental prognostic value beyond the clinical model when EASIX was added (HR 0.99; p = 0.526); this does not establish shared information between EASIX and PNI. Conclusions: Pre-transplant EASIX and mEASIX_alb are independent prognostic biomarkers in MM-ASCT. The PNI did not provide independent incremental prognostic value beyond the clinical model. These scores may inform pre-transplant risk stratification, although the illustrative cutoffs require external validation before clinical use. EASIX retained prognostic significance across transplant eras and in a cytogenetically characterized subset, supporting its era-independent and cytogenetics-independent utility.
Open AccessPre-Transplant Endothelial Activation and Stress Index (EASIX) and Albumin-Modified mEASIX (mEASIX_alb) Predict Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Background and Objectives: Endothelial dysfunction is increasingly recognized as a key determinant of transplant outcomes. The Endothelial Activation and Stress Index (EASIX), originally validated in allogeneic stem cell transplantation, integrates markers of endothelial stress into a single composite score. Its prognostic role in autologous stem cell transplantation (ASCT) for multiple myeloma (MM) remains undefined. We evaluated the pre-transplant prognostic value of EASIX, an albumin-modified formulation (mEASIX_alb), and nutritional indices (Prognostic Nutritional Index [PNI] and Controlling Nutritional Status [CONUT] score) in a large MM-ASCT cohort. Materials and Methods: We retrospectively analyzed 274 MM patients who underwent ASCT at a single institution. The pre-ASCT EASIX (LDH × Creatinine/Platelets), mEASIX_alb (LDH × Creatinine/[Platelets × Albumin]), PNI (10 × Albumin [g/dL] + 0.005 × Lymphocyte count), and CONUT score were calculated from laboratory values obtained on day 3. Optimal binary cutoffs were determined by maximally selected rank statistics. Overall survival (OS) and progression-free survival (PFS) were analyzed with Cox models in which EASIX and mEASIX_alb were entered as continuous, log-transformed variables; binary cutoffs were used only for descriptive Kaplan–Meier illustration. Internal model validity was assessed by bootstrap resampling (B = 1000). Results: Over a median follow-up of 81.3 months, 150 patients (54.7%) died, and 207 (75.5%) experienced disease progression or death. Using illustrative cutoffs (EASIX > 0.471, mEASIX_alb > 0.208, PNI < 52.29), higher EASIX was associated with shorter OS (66.7 vs. 108.1 months; p = 0.012) and PFS (27.4 vs. 42.7 months; p = 0.018). In multivariable analysis, log-transformed EASIX (HR 1.40, 95% CI 1.10–1.77; p = 0.006) and mEASIX_alb (HR 1.38, 95% CI 1.09–1.73; p = 0.007) independently predicted OS after adjustment for baseline covariates (ISS stage, pre-transplant response, and age). EASIX remained independently prognostic in a day-100 landmark analysis (HR 1.35; p = 0.023). Critically, the PNI, prognostic for OS in univariate analysis (HR 0.973; p = 0.038), did not provide independent incremental prognostic value beyond the clinical model when EASIX was added (HR 0.99; p = 0.526); this does not establish shared information between EASIX and PNI. Conclusions: Pre-transplant EASIX and mEASIX_alb are independent prognostic biomarkers in MM-ASCT. The PNI did not provide independent incremental prognostic value beyond the clinical model. These scores may inform pre-transplant risk stratification, although the illustrative cutoffs require external validation before clinical use. EASIX retained prognostic significance across transplant eras and in a cytogenetically characterized subset, supporting its era-independent and cytogenetics-independent utility.
- Open Access
- 15 June 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (9)
Defining a critical therapeutic window: cyclosporine exposure in months 1–2 as a determinant of acute graft-versus-host disease in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation from matched related donors
Acute graft-versus-host disease (aGVHD) is one of the most fatal yet preventable complications of hematopoietic stem cell transplantation (HSCT). Identifying optimal cyclosporine (CsA) blood level thresholds is particularly important in patients receiving CsA-based prophylaxis; however, cut-off values remain unclear. This retrospective study evaluated 120 patients with acute leukemia (64% acute myeloid leukemia [AML], 36% acute lymphoblastic leukemia [ALL]) who underwent allogeneic HSCT (AHSCT) between June 2011 and March 2021. CsA combined with methotrexate was used for GVHD prophylaxis. Statistical analyses included ROC analysis to determine optimal cut-off values and logistic regression to identify independent risk factors for aGVHD. aGVHD developed in 34 patients (28%), with a median onset at day 48. ROC curve analysis identified a CsA cut-off level of 274 µg/L during months 1–2, with an AUC of 0.697 (95% Confidence Interval [CI]: 0.574–0.820, p = 0.005), sensitivity of 77.3%, and specificity of 63%. In multivariate analysis, higher CsA levels during months 1–2 (Odds Ratio [OR] = 0.990, 95% CI 0.981–1.000; p = 0.039) and pre-transplant steroid use (OR = 0.284, 95% CI 0.094–0.860; p = 0.026) were independently associated with reduced risk of aGVHD. No universally accepted cut-off value of CsA levels has been defined to date, and our findings suggest that maintaining levels above 274 µg/L during the first 1–2 months post-transplant is critical to reduce aGVHD risk.
- 15 June 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (9)
Open AccessDefining a critical therapeutic window: cyclosporine exposure in months 1–2 as a determinant of acute graft-versus-host disease in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation from matched related donors
Acute graft-versus-host disease (aGVHD) is one of the most fatal yet preventable complications of hematopoietic stem cell transplantation (HSCT). Identifying optimal cyclosporine (CsA) blood level thresholds is particularly important in patients receiving CsA-based prophylaxis; however, cut-off values remain unclear. This retrospective study evaluated 120 patients with acute leukemia (64% acute myeloid leukemia [AML], 36% acute lymphoblastic leukemia [ALL]) who underwent allogeneic HSCT (AHSCT) between June 2011 and March 2021. CsA combined with methotrexate was used for GVHD prophylaxis. Statistical analyses included ROC analysis to determine optimal cut-off values and logistic regression to identify independent risk factors for aGVHD. aGVHD developed in 34 patients (28%), with a median onset at day 48. ROC curve analysis identified a CsA cut-off level of 274 µg/L during months 1–2, with an AUC of 0.697 (95% Confidence Interval [CI]: 0.574–0.820, p = 0.005), sensitivity of 77.3%, and specificity of 63%. In multivariate analysis, higher CsA levels during months 1–2 (Odds Ratio [OR] = 0.990, 95% CI 0.981–1.000; p = 0.039) and pre-transplant steroid use (OR = 0.284, 95% CI 0.094–0.860; p = 0.026) were independently associated with reduced risk of aGVHD. No universally accepted cut-off value of CsA levels has been defined to date, and our findings suggest that maintaining levels above 274 µg/L during the first 1–2 months post-transplant is critical to reduce aGVHD risk.
- Open Access
- 3 June 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Clinical outcomes and prognostic factors in hematologic malignancy patients with probable CMV pneumonia
- 3 June 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessClinical outcomes and prognostic factors in hematologic malignancy patients with probable CMV pneumonia